Guggenheim Starts CRISPR Therapeutics (CRSP) at Buy
- Wall St ticks up ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains on euro with Fed's Waller hawkish on rates
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Citi Starts CRISPR Therapeutics (CRSP) at Neutral
November 15, 2016 7:41 AM ESTCiti initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.60 yesterday.
... MorePiper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight
November 14, 2016 7:56 AM ESTPiper Jaffray initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $21.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
... MoreBarclays Starts CRISPR Therapeutics (CRSP) at Overweight
November 14, 2016 7:55 AM ESTBarclays initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $22.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
... More